Search the Newsreel

Millicom International Cellular (NasdaqGS:TIGO) Stock Price Faces Durability Questions After Cash Flow Record

Millicom International Cellular's stock dropped 7% despite reporting strong Q2 2026 results, including record adjusted EBITDA and equity free cash flow. While the company presented a bullish case with organic service revenue growth and improved margins, investors remain concerned about the durability of these …

Lineage Cell Therapeutics (LCTX) Stock Faces Cash Burn Despite Paper Profit

Cellectis 2Q Adj Loss/Shr 19c >CLLS

Cellectis reported an adjusted loss per share of 19 cents for the second quarter. The company's stock symbol is CLLS. No other financial details or forward-looking statements were provided in this brief update.

Cellectis (NASDAQ:CLLS) Releases Earnings Results, Beats Estimates By $0.04 EPS

Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS

Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside

The average 12-month price target for Celldex Therapeutics, Inc. (CLDX) stock has been raised from $57.07 to $58.07 by 15 analysts, with individual forecasts ranging from $38 to $100 per share. This new target suggests a potential upside of approximately 40% based on the …

Turkcell Iletisim Hizmetleri AS (TKC) Stock News Today

AbCellera Biologics | 8-K: Current report

This document is an 8-K current report filed by AbCellera Biologics. The content of the report itself is not provided, only the fact that it is an 8-K filing.

Barclays Initiates Cellectis(CLLS.US) With Buy Rating, Announces Target Price $9

Barclays has initiated coverage of Cellectis (CLLS.US) with a Buy rating. The firm has set a price target of $9 for the company's stock.

Omnicell (NasdaqGS:OMCL) Stock Forecast & Analyst Predictions

This article provides an in-depth analysis of Omnicell's (OMCL) stock forecast and analyst predictions, highlighting expected earnings and revenue growth, key financial updates, and recent market activities. It covers various updates including earnings guidance, price target changes, leadership appointments, and new product launches like …

Millicom Is Executing Extremely Well Across Markets

Millicom's current management team, which took over in mid-2023, has implemented a successful cost-cutting program, significantly improving profitability and cash flow without impacting revenue. These improvements are expected to continue due to attractive competitive dynamics in key markets like Guatemala and Panama. The company …

Royal Bank of Canada Sells 78,803 Shares of Omnicell, Inc. $OMCL

Royal Bank of Canada reduced its stake in Omnicell, Inc. by 12.9%, selling 78,803 shares but still retaining 532,172 shares valued at approximately $17.8 million. Other institutional investors have also adjusted their positions, and Omnicell reported strong quarterly earnings, beating analyst estimates with a …

First Trust Advisors LP Has $2.85 Million Stake in Omnicell, Inc. $OMCL

First Trust Advisors LP significantly reduced its stake in Omnicell, Inc. during the first quarter, selling over 46,000 shares but still retaining a $2.85 million position. Despite this reduction, institutional investors collectively own a substantial 97.7% of OMCL. Analyst sentiment remains largely positive, with …

Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lineage Cell Therapeutics Inc (LCTX) Stock News Today

Cellectis Reports Financial Results for the Second Quarter 2026

Cellectis, a clinical-stage biotechnology company, reported its financial results for the second quarter of 2026

Cellebrite DI Ltd. (CLBT) insider plans 653-share sale after prior dispositions

An insider at Cellebrite DI Ltd. (CLBT), David Gee, has filed to sell 653 ordinary shares, valued at $10,212.92, which are connected to vested restricted share units. This planned sale follows several prior dispositions by Gee over the last three months, totaling 5,901 shares. …

Cellebrite DI Ltd. (CLBT) insider plans sale of 1,045 vested shares

Cellebrite DI Ltd. insider Marcus Jewell intends to sell 1,045 ordinary shares through Morgan Stanley Smith Barney LLC. These shares are from restricted share units that vested on August 11, 2026, under an S-8 registered compensation plan. Jewell previously sold 383 shares on May …

Cellebrite DI Price Target Raised to $22.00/Share From $20.00 by DA Davidson

DA Davidson has increased its price target for Cellebrite DI (CLBT) shares from $20.00 to $22.00. This adjustment reflects a positive outlook on the company's future performance by the analyst firm.

Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Buy, Sell Or Hold: L&T Finance, Angel One, Cyient, Dalmia Bharat, Cello World — Ask Profit

Cellebrite DI Ltd (CLBT) Stock News Today

This page provides a comprehensive overview of Cellebrite DI Ltd. (CLBT) stock, including its current price, historical data, news, and financial information. Cellebrite specializes in developing software and services for legally sanctioned investigations, covering digital evidence collection and analysis across various crime types. The …

FuelCell Energy prices $225 million stock offering at $21 By Investing.com

FuelCell Energy Inc. (NASDAQ:FCEL) has priced an underwritten public offering of 10,714,286 shares of common stock at $21.00 per share, aiming to raise $225 million. This offering, an increase from a previously announced $200 million, will fund capital expenditures, working capital, and general corporate …

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

AbCellera Biologics (ABCL) saw its stock jump 10.3% despite reporting a significant cash burn and widening net loss in Q2 2026. The market reaction is attributed to the company's substantial cash pile of US$567 million and over US$675 million in liquidity, which is being …

Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates

Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary

Celldex Therapeutics, Inc. reported its financial results for the quarter ended 2026, with revenue of $22K and a diluted loss per share of ($0.94), resulting in a net loss of ($73.5M) due to ongoing investments in trials and manufacturing. The company highlighted clinical milestones, …

Bloom Energy Is Down 20% in a Month. Is It Time to Switch to Plug Power or FuelCell Energy?

Bloom Energy's stock has dropped 20% in the last month, despite being the only profitable company among its peers, trading at a high 303x trailing P/E. While Plug Power and FuelCell Energy appear cheaper, they are unprofitable and carry higher risk. Investors seeking diversified …

Millicom (TIGO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Investor Relations - Luca PfeiferChief Executive Officer - Marcelo BenitezChief Financial Officer - Bart Vanhaeren TAKEAWAYS Service Revenue -- $2 billion, representing a 60.1% increase on a reported basis …

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Celldex reported its second-quarter 2026 financial results, highlighting ongoing Phase 3 studies for barzolvolimab in chronic spontaneous urticaria with topline data expected in Q3/Q4 2026, and actively enrolling patients for cold urticaria and symptomatic dermographism studies. The company also announced positive Phase 1 results …

Cellectis earnings beat by $0.04, revenue fell short of estimates

Cellectis (NASDAQ: CLLS) reported Q2 EPS of $-0.220, beating analyst estimates by $0.04, but revenue of $6.9M fell short of the $10.97M consensus. The company's stock is down 30.130% in the last three months but up 1.130% over the last year. The article also …

AbCellera Biologics Inc. $ABCL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 36.8% in the first quarter, selling 878,600 shares but still retaining 1.51 million shares valued at $5.27 million. This comes as AbCellera reported weaker-than-expected quarterly results, missing both earnings per share …

FuelCell Energy Inc. stock falls Thursday, underperforms market

FuelCell Energy Inc. (FCEL) stock fell by 3.88% on Thursday, closing at $20.32. This performance underperformed the broader market, as the NASDAQ Composite Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for FuelCell Energy shares.

Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

Celldex reported a wider net loss of $

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M

Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets …

[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report